A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America

References

• Schoenberg BS. Environmental risk factors for Parkinson’s disease: the epidemiologic evidence. Can J Neurol Sci. 1987;14(3):407–413.
   PubMed Web of Science ®Google Scholar
• Von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473–490.
   PubMed Web of Science ®Google Scholar
• Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson’s disease in a Scottish city. BMJ. 1986;292(6519):534–536.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386.
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2010 Jan; p. 61. ( SIGN publication; no. 113).
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London (United Kingdom): Royal College of Physicians; 2006. ( NICE guideline; no. 242).
   Google Scholar
• Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value in Health. 2014;17(2):157–173.
   PubMed Web of Science ®Google Scholar
• Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Meab. 2014;16(5):433–442.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Bergmanb G, Huels J, et al. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin. 2009;25(8):1861–1868.
   PubMed Web of Science ®Google Scholar
• Cotlear D, Gómez-Dantés O, Knaul F, et al. Overcoming social segregation in health care in Latin America. Lancet. 2015;385:1248–1259.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org.
   Google Scholar
• Borenstein M, Hedges L, Higgins J, et al. Introduction to meta-analysis. United Kingdom: John Wiley & Sons; 2009. p. 117–119.
   Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–2508.
   PubMed Web of Science ®Google Scholar
• Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12(8):747–755.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002;59(12):1937–1943.
   PubMed Web of Science ®Google Scholar
• Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord. 2004;19(8):916–923.
   PubMed Web of Science ®Google Scholar
• Palhagen S, Heinonen E, Hägglund J, et al., et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66(8):1200–1206.
   PubMed Web of Science ®Google Scholar
• Health Information and Quality Authority. Guidelines for evaluating the clinical effectiveness of health technologies in Ireland. Dublin (Ireland): Health Information and Quality Authority; 2011.
   Google Scholar
• Friedman A. The use of levodopa in the treatment of Parkinson´s disease. Focus on Parkinson’s Dis. 2005;17(1):3–5.
   Google Scholar
• Janca A, Aarli JA, Prilipko L, et al. WHO/WFN survey of neurological services: a worldwide perspective. J Neurol Sci. 2006;247:29–34.
   PubMed Web of Science ®Google Scholar
• Singhal BS, Khadilkar SV. Neurology in the developing world. Handb Clin Neurol. 2014;121:1773–1782.
   PubMedGoogle Scholar
• Zerda A, Velásquez G, Tobar F, et al. Health insurance systems and access to medicines. Case studies from: Argentina, Chile, Colombia, Costa Rica, Guatemala and the United States of America. Washington (DC): PAHO; 2002. p. 92.
   Google Scholar
• Stewart E. The use of public health services in Latin America and the Caribbean. Perspectives from the barometer of the Americas: 2015. Lapop. 2015;110:1–9.
   Google Scholar
• Troiano R, Micheli F, Alarcón F, et al. Movement disorders in Latin America. Parkinsonism Relat Disord. 2006;12(3):125–138.
   PubMed Web of Science ®Google Scholar
• The Panamerican Health Organization. Guidelines for the implementation of strategies of generic medication in Latin American countries and the Caribbean as a mechanism to improve the access to medication. Washington (DC): The Pan American Health Organization (PAHO); 2011. ( Technical Series; no.3).
   Google Scholar
• World Health Organization. Atlas: country resources for neurological disorders. Geneva (Switzerland): World Federation of Neurology; 2004.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Xie C-L, Zhang -Y-Y, Wang X-D, et al. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis. Neurol Sci. 2015;36:1319–1329.
   PubMed Web of Science ®Google Scholar
• PD Med Collaborative Group, Gray R, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–1205.
   PubMed Web of Science ®Google Scholar
• Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137:2731–2742.
   PubMed Web of Science ®Google Scholar
• Ferguson LW, Rajput AH, Rajput A. Early-onset vs. late-onset Parkinson´s disease: a clinical-pathological study. Can J Neurol Sci. 2015: 1–7. [Epub ahead of print].
   Google Scholar